Mechanism-based pharmacokinetic–pharmacodynamic modeling of salvianolic acid A effects on plasma xanthine oxidase activity and uric acid levels in acute myocardial infarction rats

References

• Bagul PK, Middela H, Matapally S, et al. (2012). Attenuation of insulin resistance, metabolic syndrome and hepatic oxidative stress by resveratrol in fructose-fed rats. Pharmacol Res 66:260–8
   PubMed Web of Science ®Google Scholar
• Becker M, MacDonald P, Hunt B, Jackson R. (2013). Diabetes and gout: efficacy and safety of febuxostat and allopurinol. Diabetes Obes Metab 15:1049–55
   PubMed Web of Science ®Google Scholar
• Carrasco-Pozo C, Gotteland M, Speisky H. (2011). Apple peel polyphenol extract protects against indomethacin-induced damage in Caco-2 cells by preventing mitochondrial complex I inhibition. J Agric Food Chem 59:11501–8
   PubMed Web of Science ®Google Scholar
• Chae JW, Baek IH, Lee BY, et al. (2012). Population PK/PD analysis of metformin using the signal transduction model. Br J Clin Pharmacol 74:815–23
   PubMed Web of Science ®Google Scholar
• Chan D, Ng LL. (2010). Biomarkers in acute myocardial infarction. BMC Med 8:34
   PubMed Web of Science ®Google Scholar
• Chang BB, Zhang L, Cao WW, et al. (2010). Pharmacokinetic interactions induced by content variation of major water-soluble components of Danshen preparation in rats. Acta Pharmacol Sin 31:638–46
   PubMed Web of Science ®Google Scholar
• Chen YC, Cao WW, Cao Y, et al. (2011). Using neural networks to determine the contribution of danshensu to its multiple cardiovascular activities in acute myocardial infarction rats. J Ethnopharmacol 138:126–34
   PubMed Web of Science ®Google Scholar
• Chen Y, Cao Y, Zhou J, Liu X. (2009). Mechanism-based pharmacokinetic-pharmacodynamic modeling of bidirectional effect of danshensu on plasma homocysteine in rats. Pharm Res 26:1863–73
   PubMed Web of Science ®Google Scholar
• Cheng TO. (2007). Cardiovascular effects of Danshen. Int J Cardiol 121:9–22
   PubMed Web of Science ®Google Scholar
• Coolen EJ, Arts IC, Swennen EL, et al. (2008). Simultaneous determination of adenosine triphosphate and its metabolites in human whole blood by RP-HPLC and UV-detection. J Chromatogr B Analyt Technol Biomed Life Sci 864:43–51
   PubMed Web of Science ®Google Scholar
• de Oliveira EP, Burini RC. (2012). High plasma uric acid concentration: causes and consequences. Diabetol Metab Syndr 4:12
   PubMed Web of Science ®Google Scholar
• Engberding N, Spiekermann S, Schaefer A, et al. (2004). Allopurinol attenuates left ventricular remodeling and dysfunction after experimental myocardial infarction: a new action for an old drug? Circulation 110:2175–9
   PubMed Web of Science ®Google Scholar
• Fan HY, Fu FH, Yang MY, et al. (2010). Antiplatelet and antithrombotic activities of salvianolic acid A. Thromb Res 126:e17–22
   PubMed Web of Science ®Google Scholar
• Gotsman I, Keren A, Lotan C, Zwas DR. (2012). Changes in uric acid levels and allopurinol use in chronic heart failure: association with improved survival. J Card Fail 18:694–701
   PubMed Web of Science ®Google Scholar
• Halliwell B. (2008). Are polyphenols antioxidants or pro-oxidants? What do we learn from cell culture and in vivo studies? Arch Biochem Biophys 476:107–12
   PubMed Web of Science ®Google Scholar
• Hayden MR, Tyagi SC. (2004). Uric acid: A new look at an old risk marker for cardiovascular disease, metabolic syndrome, and type 2 diabetes mellitus: the urate redox shuttle. Nutr Metab (Lond) 1:10
   PubMedGoogle Scholar
• He H, Li X, Wang H, et al. (2013). Effects of salvianolic acid A on plasma and tissue dimethylarginine levels in a rat model of myocardial infarction. J Cardiovasc Pharmacol 61:482–8
   PubMed Web of Science ®Google Scholar
• Jiang B, Li D, Deng Y, et al. (2013). Salvianolic acid A, a novel matrix metalloproteinase-9 inhibitor, prevents cardiac remodeling in spontaneously hypertensive rats. PLoS One 8:e59621
   Google Scholar
• Kanbay M, Segal M, Afsar B, et al. (2013). The role of uric acid in the pathogenesis of human cardiovascular disease. Heart 99:759–66
   PubMed Web of Science ®Google Scholar
• Kaya MG, Uyarel H, Akpek M, et al. (2012). Prognostic value of uric acid in patients with ST-elevated myocardial infarction undergoing primary coronary intervention. Am J Cardiol 109:486–91
   PubMed Web of Science ®Google Scholar
• Kelkar A, Kuo A, Frishman WH. (2011). Allopurinol as a cardiovascular drug. Cardiol Rev 19:265–71
   PubMed Web of Science ®Google Scholar
• Lazaros G, Tsiachris D, Aznaouridis K, et al. (2013). Uric acid in-hospital changes predict mortality in patients with acute myocardial infarction. Nutr Metab Cardiovasc Dis 23:1202–9
   PubMed Web of Science ®Google Scholar
• Lazzeri C, Valente S, Chiostri M, et al. (2010). Uric acid in the acute phase of ST elevation myocardial infarction submitted to primary PCI: its prognostic role and relation with inflammatory markers: a single center experience. Int J Cardiol 138:206–9
   PubMed Web of Science ®Google Scholar
• Lee BE, Toledo AH, Anaya-Prado R, et al. (2009). Allopurinol, xanthine oxidase, and cardiac ischemia. J Investig Med 57:902–9
   PubMed Web of Science ®Google Scholar
• Levantesi G, Marfisi RM, Franzosi MG, et al. (2013). Uric acid: a cardiovascular risk factor in patients with recent myocardial infarction. Int J Cardiol 167:262–9
   PubMed Web of Science ®Google Scholar
• Mager DE, Wyska E, Jusko WJ. (2003). Diversity of mechanism-based pharmacodynamic models. Drug Metab Dispos 31:510–18
   PubMed Web of Science ®Google Scholar
• Milligan P, Brown M, Marchant B, et al. (2013). Model-based drug development: a rational approach to efficiently accelerate drug development. Clin Pharmacol Therap 93:502–14
   PubMed Web of Science ®Google Scholar
• Nieto FJ, Iribarren C, Gross MD, et al. (2000). Uric acid and serum antioxidant capacity: a reaction to atherosclerosis? Atherosclerosis 148:131–9
   PubMed Web of Science ®Google Scholar
• Puddu P, Puddu GM, Cravero E, et al. (2012). The relationships among hyperuricemia, endothelial dysfunction, and cardiovascular diseases: molecular mechanisms and clinical implications. J Cardiol 59:235–42
   PubMed Web of Science ®Google Scholar
• Rajman I. (2008). PK/PD modelling and simulations: utility in drug development. Drug Discov Today 13:341–6
   PubMed Web of Science ®Google Scholar
• Sun L, Zhao R, Zhang L, et al. (2012). Salvianolic acid A inhibits PDGF-BB induced vascular smooth muscle cell migration and proliferation while does not constrain endothelial cell proliferation and nitric oxide biosynthesis. Molecules 17:3333–47
   PubMed Web of Science ®Google Scholar
• Wang J, Jiang Z, Ji J, et al. (2012). Evaluation of hepatotoxicity and cholestasis in rats treated with EtOH extract of Fructus Psoraleae. J Ethnopharmacol 144:73–81
   PubMed Web of Science ®Google Scholar
• Wang SB, Tian S, Yang F, et al. (2009a). Cardioprotective effect of salvianolic acid A on isoproterenol-induced myocardial infarction in rats. Eur J Pharmacol 615:125–32
   PubMed Web of Science ®Google Scholar
• Wang SB, Yang XY, Tian S, et al. (2009b). Effect of salvianolic acid A on vascular reactivity of streptozotocin-induced diabetic rats. Life Sci 85:499–504
   PubMed Web of Science ®Google Scholar
• Wu B, Liu M, Zhang S. (2004). Dan Shen agents for acute ischaemic stroke. Cochrane Library CD004295
   Google Scholar
• Yamazaki S, Nguyen L, Vekich S, et al. (2011). Pharmacokinetic-pharmacodynamic modeling of biomarker response and tumor growth inhibition to an orally available heat shock protein 90 inhibitor in a human tumor xenograft mouse model. J Pharmacol Exp Ther 338:964–73
   PubMed Web of Science ®Google Scholar
• Yang LL, Li DY, Zhang YB, et al. (2012a). Salvianolic acid A inhibits angiotensin II-induced proliferation of human umbilical vein endothelial cells by attenuating the production of ROS. Acta Pharmacol Sin 33:41–8
   PubMed Web of Science ®Google Scholar
• Yang T, Chu CH, Bai CH, et al. (2012b). Uric acid concentration as a risk marker for blood pressure progression and incident hypertension: a Chinese cohort study. Metab Clin Exp 61:1747–55
   PubMed Web of Science ®Google Scholar
• Zhou L, Zuo Z, Chow MSS. (2005). Danshen: an overview of its chemistry, pharmacology, pharmacokinetics, and clinical use. J Clin Pharmacol 45:1345–59
   PubMed Web of Science ®Google Scholar